Close Menu

product launch

Backed by Andreessen Horowitz and Polaris Partners, Camp4 hopes its high-resolution gene maps can shorten and remove risk from the drug development process.

PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.

The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.

The company cites flexibility and ease of use as its main selling points, and is partnering with IVD firms like Randox and R-Biopharm on assay development.

The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.

Amplidiag CarbaR+MCR detects the main carbapenemase-producing organisms and colistin resistance markers. Novidiag Bacterial GE+ identifies the most common enteric pathogens.

At HIMSS18, Eric Schmidt announced a new healthcare API for Google Cloud and explored how predictive analytics might change medical care and research for the better.

Startup Optra Health has added Alexa and Cortana compatibility to its AI platform to help consumers understand Ancestry.com- and 23andMe-type genetic tests.

Anitoa's handheld Maverick platform weighs one kilogram and comes with cloud-based analysis software.

The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.